Featured Post:

Opening LUGPA 2026: A Real-World Case Study in Smarter Prostate Cancer Detection

By: Joe Abdo, PhD

Dr. Garrett Pohlman delivers Podium Presentation #1 at the Global Prostate Cancer Congress, highlighting real-world integration of EpiSwitch® PSE in large urology practices

Read Post

Stay In the Loop

Subscribe to receive our latest blog posts covering a wide range of topics, from groundbreaking discoveries to cutting-edge advancements and industry trends.

PREVIOUS POSTS

How Imperial College Healthcare Private Care embedded PSE into its workflow

25 Mar 2026
4 Minutes

This Prostate Cancer Test is 270% Better Than PSA

18 Dec 2025
4 Minutes

Redefining Cancer Screening in the Clinic and at Home

04 Dec 2025
5 Minutes

Men's Health Month: A conversation with Prostate Cancer advocate Alfred Samuels

03 Oct 2025
3 Minutes

Prostate Cancer in 2025: What Every Man Needs to Know

24 June 2025
5 Minutes

Unveiling Cancer’s Hidden Secrets in Your Blood

10 April 2025
6 Minutes

Physicians and Researchers Find EpiSwitch® CiRT Assay to be a Helpful Tool

22 January 2025
4 Minutes

The Critical Fight Against Prostate Cancer in African American Men

09 December 2024
7 Minutes

The Immunobuddies Podcast discusses benefits of CiRT for immunotherapy

28 October 2024
8 Minutes

The unequal burden: Prostate cancer hits Black men harder. Can the gap be closed?

2 October 2024
5 Minutes

Strides for Screening: Raising Awareness for Early Prostate Cancer Detection

18 September 2024
6 Minutes

The Vital Role of Patient Advocacy Groups in Prostate Cancer Care

14 June 2024
1 Minute

No Tissue? No Problem: How a first-of-its-kind blood test optimizes patient management in oncology

3 June 2024
7 Minutes

Revolutionizing Prostate Cancer Detection: Dr. Heaton's Fireside Chat on the PSE Test

16 April 2024
4 Minutes

The Hope of Immunotherapy Sold to Cancer Patients on National TV: But Does it Work for Everybody?

14 March 2024
2 Minutes

Unveiling Expert Insights on the PSE Test With Dr. Pohlman and Dr. Heaton

08 February 2024
2 Minutes

Time to Rethink Prostate Cancer Testing: A Q and A With OBD's CSO, Alexandre Akoulitchev, PhD, FRSM

09 November 2023
5 Minutes

"Touchdowns for Hope”: The Montgomery Village 8U Football Team's Inspiring Journey to #BEATCANCER

27 October 2023
5 Minutes

How EpiSwitch® Blood Markers Advance Precision Medicine and Cancer Care

16 June 2023
6 Minutes

IN THE NEWS

New Liquid Biopsy Test Can Improve Prostate Cancer Test Accuracy from 55% to 94%; Revolutionary Test Based on 3D Genomics Is Described at Precision Medicine World Conference (PMWC 2024)

BioQuick News | Jan 25, 2024

View Article

Q&A: Analyzing Blood, Not the Tumor: A Novel Test for Personalized Cancer Immunotherapy

GenomeWeb | Sep 1, 2023

View Article

New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies

Cancerworld | Feb 23, 2023

View Article

About Oxford BioDynamics

Computer screen with closeup of 3D genome and chromatin loops. Gloved hands typing at computer keyboard

Oxford BioDynamics PLC (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship products are the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Cancer Detection Test) blood tests. CiRT predicts how a patient will respond to immune checkpoint inhibitor therapies. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer.

OBD's proprietary EpiSwitch® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring. For more information, please visit myOBDX.com.

Learn About OBD